How Climaco was paid
$1.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Total |
|---|---|---|---|---|
| John ClimacoFormer Chief Executive Officer | $580,000 | $269,591 | $319,000 | $1,168,591 |
| Christopher DownsSenior Vice President – Finance, Former Chief Financial Officer | $450,000 | $134,809 | $144,000 | $728,809 |
| Sandra SilbermanFormer Chief Medical Officer | $495,000 | $67,418 | $158,400 | $720,818 |
What changed and why
- $1.2M$1,168,591 was John Climaco’s 2025 total compensation, versus $1,103,680 in 2024.
- $319K$319,000 was Climaco’s 2025 non-equity incentive compensation and cash bonus under his separation agreement.
- 50%50% was Climaco’s target bonus; his 2025 award represented 100% of potential.
- 40%40% was the target bonus for Downs and Silberman; each received 80% of potential for 2025.
- $270KNovember 2025 option grants accounted for $269,591 of Climaco’s reported compensation.
- 50%Rami Levin became CEO January 1, 2026, with a $580,000 salary, 50% target bonus, and 19,000 initial RSUs.
Other CNS Pharmaceuticals proxy statements
- 2025 proxy statement
John Climaco paid $1.1M (+77% on the year).
Filed Oct 24, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.